ESR1 and breast carcinoma: A large-scale study identified that mutations in four genes (ESR1, CDH1, RICTOR, and TP53) tended to occur in specific metastatic sites, which could be biomarkers or therapeutic targets of metastatic breast cancer patients (Cha et al., 2021).